

Data Section

Major Products

Innovative Pharmaceuticals Business

Brand Name (Generic Name)	Efficacy	Launched	Remarks
Japan [Daiichi Sankyo Co., Ltd.]			
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2014	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>PRALIA</i> (<i>denosumab</i>)	Treatment for osteoporosis	2013	Human monoclonal anti-RANKL antibody. This agent controls bone resorption by specifically inhibiting RANKL, resulting in the suppressed formation of osteoclasts. The agent is indicated for the treatment of patients with osteoporosis as well as those with rheumatoid arthritis-induced progression of bone erosions. <i>Denosumab</i> as a single subcutaneous injection once every 6 months is shown to suppress the progression of bone erosions along with inhibiting fracture risks. (single subcutaneous administration every three months is permitted in patients with advanced bone erosion)
<i>TENELIA</i> (<i>teneligliptin</i>)	Type 2 diabetes mellitus treatment	2012	DPP-4 inhibitor. The agent inhibits the activity of DPP-4 (dipeptidyl peptidase-4), an enzyme that inactivates incretin (GLP-1, GIP), which is a glucose-dependent insulin-releasing hormone excreted from the gastrointestinal tract, and thereby increases incretin concentration in blood and facilitates insulin release. In September 2017, <i>CANALIA</i> combination tablets that combine <i>TENELIA</i> and a SGLT2 inhibitor, <i>CANAGLU</i> , for the treatment of type-2 diabetes were launched.
<i>RANMARK</i> (<i>denosumab</i>)	Treatment for bone complications caused by bone metastases from tumors	2012	Human monoclonal anti-RANKL antibody. A new and effective treatment option for treating bone disorders stemming from multiple myeloma and bone metastases from solid tumors.
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2011	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly, and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for the prevention of venous thromboembolism (VTE) in patients with lower limb orthopedic surgery.
		2014	Approved for additional indications for the prevention of ischemic stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVA) and for the treatment and recurrence prevention of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary thromboembolism).
<i>NEXIUM</i> (<i>esomeprazole</i>)	Ulcer treatment	2011	Proton pump inhibitor. Licensed from AstraZeneca. It suppresses gastric acid secretion.
<i>Memary</i> (<i>memantine</i>)	Alzheimer's disease treatment	2011	N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine slows down progression of dementia symptoms in patients with moderate to severe Alzheimer's disease.
<i>Inavir</i> (<i>laninamivir</i>)	Anti-influenza treatment	2010	Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.
<i>Urief</i> (<i>silodosin</i>)	Treatment for dysuria	2006	Selective alpha 1A-adrenoceptor antagonist that selectively blocks alpha 1A-adrenoceptors in the lower part of the urinary tract. Compared with other alpha blockers, it causes fewer side effects, such as orthostatic hypotension.
<i>Olmotec</i> (<i>olmesartan</i>)	Antihypertensive agent	2004	Angiotensin II receptor blocker. <i>Olmесartan</i> blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the angiotensin II receptor.
<i>Rezaltas</i>		2010	A combination of two antihypertensive drugs: calcium ion antagonist, <i>azelnidipine</i> , and an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> .
<i>Cravit</i> (<i>levofloxacin</i>)	Synthetic antibacterial agent	1993	New quinolone antibacterial agent offering strong antibacterial action and a broad antibacterial spectrum. Injectable preparation has been added as part of life-cycle management.
<i>Mevalotin</i> (<i>pravastatin</i>)	Antihyperlipidemic agent	1989	HMG-CoA reductase inhibitor (statin) that lowers blood cholesterol levels by inhibiting cholesterol synthesis in the liver.
<i>Omnipaque</i> (<i>iohexol</i>)	Contrast medium	1987	Nonionic contrast medium used to improve visibility of diagnostic X-ray imaging is inadequate.
<i>Loxonin</i> (<i>loxoprofen</i>)	Anti-inflammatory analgesic	1986	Nonsteroidal anti-inflammatory analgesic. <i>Loxonin</i> tablets and granules have strong analgesic activity with lowered gastric side effects. <i>Loxoprofen</i> is a prodrug and is not metabolized in the stomach but activated after absorption through the small intestine. Other formulations such as tape are also available as a part of life-cycle management.



Olmotec (Japan)




NEXIUM (Japan)



PRALIA (Japan)



Effient (Japan)



LIXIANA (Japan)



Memary (Japan)



RANMARK (Japan)



TENELIA (Japan)

Innovative Pharmaceuticals Business

Brand Name (Generic Name)	Efficacy	Launched	Remarks
US [Daiichi Sankyo Inc.]			
<i>MOVANTIK</i> (<i>naloxegol</i>)	Opioid-induced constipation treatment	2015	First once-daily oral product approved by the FDA for the treatment of opioid-induced constipation(OIC) for adults with chronic non-cancer pain.
<i>SAVAYSA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVA) and for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Benicar</i>		2002	<i>Benicar</i> : <i>Olmесartan</i>
<i>Benicar HCT</i>		2003	<i>Benicar HCT</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>AZOR</i> (<i>olmesartan</i>)	Antihypertensive agent	2007	<i>AZOR</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>TRIBENZOR</i>		2010	<i>TRIBENZOR</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>
<i>Welchol</i> (<i>colesevelam</i>)	Hypercholesterolemia treatment / type 2 diabetes mellitus treatment	2000	Bile acid sequestrant. Marketed as a drug for treatment of hypercholesterolemia. Gained approval also for type 2 diabetes mellitus indication as part of life-cycle management.
US [Luitpold Pharmaceuticals, Inc.]			
<i>Injectafer</i> (<i>feric carboxymaltose injection</i>)	Anemia treatment	2013	Effective for patients who have intolerance to oral iron or who have had unsatisfactory response to oral iron or who have non-dialysis-dependent chronic kidney disease.
<i>Venofer</i> (<i>iron sucrose injection</i>)	Anemia treatment	2000	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients.
Europe [Daiichi Sankyo Europe GmbH]			
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications for the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVA) and for the treatment and prevention of recurrent venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Olmotec</i>		2002	<i>Olmotec</i> : <i>Olmесartan</i>
<i>Olmotec Plus</i>		2005	<i>Olmotec Plus</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>Sevikar</i> (<i>olmesartan</i>)	Antihypertensive agent	2009	<i>Sevikar</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>Sevikar HCT</i>		2010	<i>Sevikar HCT</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>

Generic Business

Brand Name (Efficacy)
Japan [Daiichi Sankyo Espha Co., Ltd.]
<i>Olmесartan</i> (Antihypertensive agent)
<i>Rosuvastatin</i> (Antihyperlipidemic agent)
<i>Telmisartan</i> (Antihypertensive agent)
<i>Levofloxacin</i> (Synthetic antibacterial agent)
<i>Donepezil</i> (Alzheimer's disease treatment)

OTC Related Business

Brand Name
Japan [Daiichi Sankyo Healthcare Co., Ltd.]
<i>Lulu</i> (Combination cold remedy)
<i>Loxonin S</i> (Antipyretic analgesic/Topical anti-inflammatory analgesic)
<i>Transino</i> (Medicine for improving melasma/alleviating spots, freckles, pigmentation)
<i>Minon</i> (Moisturizing cleanser)
<i>Clean Dental</i> (Oral care product)

Vaccine Business

Brand Name (Efficacy)
Japan [Kitasato Daiichi Sankyo Vaccine Co., Ltd., Japan Vaccine Co., Ltd.]
<i>Influenza HA Vaccine</i> (Seasonal influenza vaccine)
<i>Rotarix Oral Liquid</i> (Vaccine for prevention of rotavirus gastroenteritis in infants and young children)
<i>ActHIB</i> (Haemophilus influenzae type b vaccine for children)
<i>Live Attenuated Measles-Rubella Combined Vaccine</i> (Measles and rubella vaccine)
<i>Squarekids</i> (4-valent combination vaccine for the prevention of pertussis, diphtheria, tetanus and poliomyelitis (polio))



MOVANTIK (US)



LIXIANA (Europe)



Loxonin S (OTC Related Drugs)



Lulu (OTC Related Drugs)



Injectafer (US)



olmesartan (Generic Drugs)



Transino (OTC Related Drugs)



Influenza HA Vaccine (Vaccines)